|
Metastatic Melanoma – Pipeline Review, H1 2012
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
Zahlen und Fakten zur Studie: | 141 seiten | |||||||||
| Inhalt der Studie: |
Introduction
Global Markets Direct’s, 'Metastatic Melanoma - Pipeline Review, H1 2012', provides an overview of the Metastatic Melanoma therapeutic pipeline. This report provides information on the t.....
Introduction Global Markets Direct’s, 'Metastatic Melanoma - Pipeline Review, H1 2012', provides an overview of the Metastatic Melanoma therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Melanoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Melanoma. 'Metastatic Melanoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Metastatic Melanoma. - A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Metastatic Melanoma pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Highlights Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Metastatic Melanoma therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. [Studien Infos ausblenden] |
|||||||||||
|
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Metastatic Melanoma Overview 10 Therapeutics Development 11 An Overview of Pipeline Products for Metastatic Melanoma 11 Metastatic Melanoma Therapeutics under Development by Companies 13 Metastatic Melanoma Therapeutics under Investigation by Universities/Institutes 17 Late Stage Products 24 Comparative Analysis 24 Mid Clinical Stage Products 25 Comparative Analysis 25 Early Clinical Stage Products 26 Comparative Analysis 26 Discovery and Pre-Clinical Stage Products 27 Comparative Analysis 27 Metastatic Melanoma Therapeutics – Products under Development by Companies 28 Metastatic Melanoma Therapeutics – Products under Investigation by Universities/Institutes 32 Companies Involved in Metastatic Melanoma Therapeutics Development 44 Bristol-Myers Squibb Company 44 F. Hoffmann-La Roche Ltd. 45 Abbott Laboratories 46 Vical Incorporated 47 Adherex Technologies Inc. 48 Viralytics Ltd. 49 GlaxoSmithKline plc 50 Genentech, Inc. 51 MedImmune LLC 52 Emergent BioSolutions Inc. 53 Millennium Pharmaceuticals, Inc. 54 Novartis AG 55 ImClone Systems Incorporated 56 Pain Therapeutics, Inc. 57 Celgene Corporation 58 3SBio Inc. 59 EpiCept Corporation 60 Celldex Therapeutics, Inc. 61 Molecular Insight Pharmaceuticals, Inc. 62 Northwest Biotherapeutics, Inc. 63 Osta Biotechnologies Inc. 64 Advanced Life Sciences Holdings, Inc. 65 Progen Pharmaceuticals Limited 66 Threshold Pharmaceuticals, Inc. 67 Provectus Pharmaceuticals, Inc. 68 BioAlliance Pharma SA 69 Piramal Life Sciences Limited 70 Morphotek, Inc. 71 Antisense Pharma GmbH 72 Philogen S.p.A. 73 Curacyte AG 74 Cytheris SA 75 Altor BioScience Corporation 76 Affichem 77 Myriad Pharmaceuticals, Inc. 78 Omeros Corporation 79 Immunocore Limited. 80 CureTech Ltd. 81 Medisyn Technologies, Inc. 82 Cytavis Biopharma GmbH 83 Gradalis Inc. 84 Lipotek Pty Ltd 85 Metastatic Melanoma – Therapeutics Assessment 86 Assessment by Monotherapy Products 86 Assessment by Combination Products 87 Assessment by Route of Administration 88 Assessment by Molecule Type 91 Drug Profiles 94 GSK1120212 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 Allovectin-7 - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Zelboraf - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 Abraxane - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 NuLeusin - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 Aldesleukin + Vaccine Therapy - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 GP100 Antigen + Incomplete Freund's adjuvant + Aldesleukin - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 Aldesleukin + Ceplene - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 MDX-010 + DTIC - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 Aldesleukin + Gp100 Antigen + Incomplete Freund's Adjuvant - Drug Profile 106 Product Description 106 Mechanism of Action 106 R&D Progress 107 MART-1 Antigen + GP-100 Antigen + Tyrosinase Peptide + GM-CSF + Incomplete Freund's Adjuvant - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 GSK2118436 - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 Interleukin-2 - Drug Profile 112 Product Description 112 Mechanism of Action 112 R&D Progress 112 Metastatic Melanoma Therapeutics – Drug Profile Updates 113 Metastatic Melanoma Therapeutics – Discontinued Products 118 Metastatic Melanoma Therapeutics - Dormant Products 120 Metastatic Melanoma – Product Development Milestones 133 Featured News & Press Releases 133 Dec 16, 2011: Roche's Zelboraf Receives Positive Opinion From European Authority For Treatment Of People With BRAF Mutation-Positive Metastatic Melanoma 133 Nov 29, 2011: Provectus Reports On Third End-Of-Phase II Meeting With FDA To Define Pathway To Approval Of PV-10 for Metastatic Melanoma 133 Nov 22, 2011: Researchers Identify P Rex-1 Protein That Contributes To Development Of Melanoma 134 Nov 14, 2011: Provectus Presents Data On PV-10 For Metastatic Melanoma At 2011 International Melanoma Congress 134 Nov 10, 2011: Phase II Data on Provectus’s PV-10 For Metastatic Melanoma To Be Presented At 2011 International Melanoma Congress 135 Sep 13, 2011: BioAlliance Announces Positive Preliminary Phase I Clinical Results With AMEP Biotherapy For Metastatic Melanoma 135 Aug 17, 2011: Roche Announces FDA Approval For Zelboraf And Companion Diagnostic For BRAF Mutation-Positive Metastatic Melanoma 136 Aug 02, 2011: Jennerex Reports Positive Mechanistic Proof Of Concept Clinical Trial Results Using JX-594 To Treat Metastatic Melanoma 137 Jul 13, 2011: CYTAVIS's Aviscumine Improves Survival Of Patients With Metastatic Melanoma In Phase II Trial 138 Jun 29, 2011: Provectus Presents Additional Data On PV-10 For Metastatic Melanoma At Prominent Melanoma Conferences 139 Appendix 140 Methodology 140 Coverage 140 Secondary Research 140 Primary Research 140 Expert Panel Validation 141 Contact Us 141 Disclaimer 141 [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
List of Tables Number of Products Under Development for Metastatic Melanoma, H1 2012 11 Products under Development for Metastatic Melanoma – Comparative Analysis, H1 2012 12 Number of Products under Development by Companies, H1 2012 14 Number of Products under Development by Companies, H1 2012 (Contd..1) 15 Number of Products under Development by Companies, H1 2012 (Contd..2) 16 Number of Products under Investigation by Universities/Institutes, H1 2012 18 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 19 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 21 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 22 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 23 Comparative Analysis by Late Stage Development, H1 2012 24 Comparative Analysis by Mid Clinical Stage Development, H1 2012 25 Comparative Analysis by Early Clinical Stage Development, H1 2012 26 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 27 Products under Development by Companies, H1 2012 28 Products under Development by Companies, H1 2012 (Contd..1) 29 Products under Development by Companies, H1 2012 (Contd..2) 30 Products under Development by Companies, H1 2012 (Contd..3) 31 Products under Investigation by Universities/Institutes, H1 2012 32 Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 33 Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 34 Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 35 Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 36 Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 37 Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 38 Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 39 Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 40 Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 41 Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 42 Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 43 Bristol-Myers Squibb Company, H1 2012 44 F. Hoffmann-La Roche Ltd., H1 2012 45 Abbott Laboratories, H1 2012 46 Vical Incorporated, H1 2012 47 Adherex Technologies Inc., H1 2012 48 Viralytics Ltd., H1 2012 49 GlaxoSmithKline plc, H1 2012 50 Genentech, Inc., H1 2012 51 MedImmune LLC, H1 2012 52 Emergent BioSolutions Inc., H1 2012 53 Millennium Pharmaceuticals, Inc., H1 2012 54 Novartis AG, H1 2012 55 ImClone Systems Incorporated, H1 2012 56 Pain Therapeutics, Inc., H1 2012 57 Celgene Corporation, H1 2012 58 3SBio Inc., H1 2012 59 EpiCept Corporation, H1 2012 60 Celldex Therapeutics, Inc., H1 2012 61 Molecular Insight Pharmaceuticals, Inc., H1 2012 62 Northwest Biotherapeutics, Inc., H1 2012 63 Osta Biotechnologies Inc., H1 2012 64 Advanced Life Sciences Holdings, Inc., H1 2012 65 Progen Pharmaceuticals Limited, H1 2012 66 Threshold Pharmaceuticals, Inc., H1 2012 67 Provectus Pharmaceuticals, Inc., H1 2012 68 BioAlliance Pharma SA, H1 2012 69 Piramal Life Sciences Limited, H1 2012 70 Morphotek, Inc., H1 2012 71 Antisense Pharma GmbH, H1 2012 72 Philogen S.p.A., H1 2012 73 Curacyte AG, H1 2012 74 Cytheris SA, H1 2012 75 Altor BioScience Corporation, H1 2012 76 Affichem, H1 2012 77 Myriad Pharmaceuticals, Inc., H1 2012 78 Omeros Corporation, H1 2012 79 Immunocore Limited., H1 2012 80 CureTech Ltd., H1 2012 81 Medisyn Technologies, Inc., H1 2012 82 Cytavis Biopharma GmbH, H1 2012 83 Gradalis Inc., H1 2012 84 Lipotek Pty Ltd, H1 2012 85 Assessment by Monotherapy Products, H1 2012 86 Assessment by Combination Products, H1 2012 87 Assessment by Stage and Route of Administration, H1 2012 90 Assessment by Molecule Type, H1 2012 93 Metastatic Melanoma Therapeutics – Drug Profile Updates 113 Metastatic Melanoma Therapeutics – Discontinued Products 118 Metastatic Melanoma Therapeutics – Discontinued Products (Contd..1) 119 Metastatic Melanoma Therapeutics – Dormant Products 120 Metastatic Melanoma Therapeutics – Dormant Products (Contd..1) 121 Metastatic Melanoma Therapeutics – Dormant Products (Contd..2) 122 Metastatic Melanoma Therapeutics – Dormant Products (Contd..3) 123 Metastatic Melanoma Therapeutics – Dormant Products (Contd..4) 124 Metastatic Melanoma Therapeutics – Dormant Products (Contd..5) 125 Metastatic Melanoma Therapeutics – Dormant Products (Contd..6) 126 Metastatic Melanoma Therapeutics – Dormant Products (Contd..7) 127 Metastatic Melanoma Therapeutics – Dormant Products (Contd..8) 128 Metastatic Melanoma Therapeutics – Dormant Products (Contd..9) 129 Metastatic Melanoma Therapeutics – Dormant Products (Contd..10) 130 Metastatic Melanoma Therapeutics – Dormant Products (Contd..11) 131 Metastatic Melanoma Therapeutics – Dormant Products (Contd..12) 132 List of Figures Number of Products under Development for Metastatic Melanoma, H1 2012 11 Products under Development for Metastatic Melanoma – Comparative Analysis, H1 2012 12 Products under Development by Companies, H1 2012 13 Products under Investigation by Universities/Institutes, H1 2012 17 Late Stage Products, H1 2012 24 Mid Clinical Stage Products, H1 2012 25 Early Clinical Stage Products, H1 2012 26 Discovery and Pre-Clinical Stage Products, H1 2012 27 Assessment by Monotherapy Products, H1 2012 86 Assessment by Combination Products, H1 2012 87 Assessment by Route of Administration, H1 2012 88 Assessment by Stage and Route of Administration, H1 2012 89 Assessment by Molecule Type, H1 2012 91 Assessment by Stage and Molecule Type, H1 2012 92 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
